BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19849996)

  • 1. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
    Arnou R; Icardi G; De Decker M; Ambrozaitis A; Kazek MP; Weber F; Van Damme P
    Vaccine; 2009 Dec; 27(52):7304-12. PubMed ID: 19849996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
    Leroux-Roels I; Vets E; Freese R; Seiberling M; Weber F; Salamand C; Leroux-Roels G
    Vaccine; 2008 Dec; 26(51):6614-9. PubMed ID: 18930093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
    N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
    Morelon E; Pouteil Noble C; Daoud S; Cahen R; Goujon-Henry C; Weber F; Laurent PE; Kaiserlian D; Nicolas JF
    Vaccine; 2010 Oct; 28(42):6885-90. PubMed ID: 20709000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
    Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum antibody responses after intradermal vaccination against influenza.
    Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
    N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
    Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenicity of intradermal influenza vaccination in COPD patients.
    Chuaychoo B; Wongsurakiat P; Nana A; Kositanont U; Maranetra KN
    Vaccine; 2010 May; 28(24):4045-51. PubMed ID: 20412877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
    Chi RC; Rock MT; Neuzil KM
    Clin Infect Dis; 2010 May; 50(10):1331-8. PubMed ID: 20377407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
    Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM
    J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
    Sugimura T; Ito Y; Tananari Y; Ozaki Y; Maeno Y; Yamaoka T; Kudo Y
    Vaccine; 2008 May; 26(22):2700-5. PubMed ID: 18436353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
    J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
    Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.